Company intelligence / Profile preview

Galo Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Galo Therapeutics is a biotechnology company focused on developing novel therapies that modulate macrophage biology to treat inflammatory and fibrotic diseases. Founded by industry veterans from Alnylam Pharmaceuticals, the company leverages a proprietary platform to selectively target and reprogram macrophages within diseased tissues. By shifting these cells from a pro-inflammatory to a pro-resolving state, Galo aims to address the underlying drivers of chronic disease and restore tissue homeostasis. The company is currently in the pre-clinical stage, supported by leading venture capital firms including F-Prime Capital and Eight Roads Ventures.

Therapeutic areas: ImmunologyOtherMetabolic Disorders
Modalities: Small moleculeBiologicConjugate
Industry: Biotech

Beyond the preview

Go deeper on Galo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galo Therapeutics.

Explore the full profile